Beta Bionics, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
BBNX$16.52-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2025 and 2024
BALANCE SHEETS
(In thousands, except number of shares)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $31,576 | $30,432 |
| Restricted cash, current | 100 | — |
| Short-term investments | 187,549 | 73,143 |
| Accounts receivable, net | 17,118 | 11,996 |
| Inventories | 21,722 | 13,320 |
| Prepaid expenses and other current assets | 9,840 | 4,032 |
| Total current assets | 267,905 | 132,923 |
| Property and equipment, net | 8,600 | 4,776 |
| Operating lease right-of-use asset | 6,627 | 6,645 |
| Restricted cash, noncurrent | — | 100 |
| Deferred offering costs | — | 5,051 |
| Long-term investments | 45,431 | — |
| Other long-term assets | 180 | 150 |
| Total assets | 328,743 | $149,645 |
| Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | $4,998 | $2,852 |
| Accrued expenses and other current liabilities | 22,431 | 15,828 |
| Operating lease liabilities | 1,938 | 1,529 |
| Deferred revenue | 1,557 | 939 |
| Total current liabilities | 30,924 | 21,148 |
| Operating lease liabilities, net of current portion | 5,365 | 5,726 |
| Deferred revenue, net of current portion | 3,297 | 1,860 |
| Warrant liabilities | — | 44,898 |
| Other long-term liabilities | 1,547 | — |
| Total liabilities | 41,133 | 73,632 |
| Commitments and contingencies (Note 18) | ||
| Convertible preferred stock (Series A, A-2, B, B-2, C, D and E), par value of $0.0001 per share; no and 34,966,547 shares authorized at December 31, 2025 and December 31, 2024, respectively; no and 17,228,954 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively; liquidation preference of $0 and $355,162 at December 31, 2025 and December 31, 2024, respectively | — | 321,373 |
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and 2024 | — | — |
| Common stock, $0.0001 par value, 700,000,000 shares authorized; 44,360,873 and 6,667,793 issued and outstanding at December 31, 2025 and 2024, respectively | 4 | 1 |
| Additional paid-in capital | 657,140 | 51,311 |
| Accumulated other comprehensive income | 403 | 65 |
| Accumulated deficit | (369,937) | (296,737) |
| Total stockholders’ equity (deficit) | 287,610 | (245,360) |
| Total liabilities, convertible preferred stock and stockholders’ equity (deficit) | $328,743 | $149,645 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.